adjust dilut earn per share ep defin report
relat cost discontinu oper certain signific
revenu sale ahead estim ep guidanc rais
ep estim consensu ep guidanc
rais vs prior rais ep estim
estim review
sale estim
consensu product beat estim includ eliqui lipitor xalkori
norvasc xeljanz prevnar viagra enbrel chantix zyvox inlyta celebrex
combin forecast product forecast includ lyrica
premarin sutent ibranc xtandi combin
forecast sale guidanc lower greater
neg fx impact prior last publish revenu
estim
gpm estim
estim sg estim net non-
oper incom estim includ sever one time
item tax rate estim share count
estim guidanc updat prior
net incom tax rate prior
bavencio avelumab ph data ovarian ph data combo w/
ibranc ph ii data pallet neoadjuv bc pancreat cancer xeljanz ph
extens data uc eu approv uc posit chmp june lorlatinib /eu/jp
approv alk nsclc pdufa aug biosimilar file avastin biosimilar
dacomitinib /eu approv egfr nsclc pdufa sept xtandi eu approv
non-metastat talazoparib parp /eu approv mbrca bc pdufa
ph data sickl cell diseas tafamidi full ph data attr-act ttr
cardiomyopathi posit top-lin apr regulatori file trumenba initi ph
yo consum divis decis futur statu
pleas see page report import disclosur
outperform rate stock key averag bottom-lin growth
improv innovation/new product flow solid dividend yield
compel valuat share appear under-valued sotp basi
xtandi eu approv non-metastat
tafamidi full ph data regulatori
file ttr cardiomyopathi
decis consum busi futur
everi earli stage product
launch achiev
ibranc palbociclib adopt even
brisk expect
pipelin achiev greater expect
accret potenti break-up
compani lead greater valuat
pfizer inc global biopharmaceut compani divers portfolio pharma product
cover area cardiovascular anti-infect anti-inflammatori oncolog
metabol diseas other also strong vaccin portfolio consum product
segment array brand product
cowen compani
chgpfizer innov essenti expens inc mm cowen
cowen compani
cowen compani
chgnet cowen
cowen compani
chgnet cowen
cowen compani
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ success pipelin product patent expir greater
expect impact ep success streamlin and/or separ busi
structur outcom potenti
